“We are excited to bring ToolGen’s CRISPR platform on board at Monsanto, and are continuing to bolster and diversify our capabilities in this field of research,” said Tom Adams, Ph.D., vice president of biotechnology for Monsanto. “As a company we remain committed to the development of safe, sustainable and high-quality crops, and look forward to leveraging the CRISPR platform as we endeavor to meet the needs of farmers while answering consumer demand for food options.”
ToolGen is an early pioneer in gene editing research and this license provides Monsanto with access to ToolGen’s comprehensive suite of CRISPR intellectual property for use in plants. This agreement further expands Monsanto’s broad portfolio of gene-editing tools for developing improved and sustainable crops.